RAPP — Rapport Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2012593 ·
Last close
$23.76
Market Cap
$1.41B
52W High
$52.93
52W Low
$22.06
ADV30
1,197,969
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -44,086,000 -40,235,000 418,558,000 74,754,000 27,368,000
Jun 2026 0 — -60,806,000 -56,615,000 458,982,000 63,612,000 36,056,000
Mar 2026 20,000,000 — -24,215,000 -19,857,000 497,597,000 78,056,000 26,085,000
Dec 2025 0 — -38,509,000 -33,763,000 512,431,000 52,645,000 27,778,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-120,850,000
Investing CF
$-59,719,000
Financing CF
$3,964,000
CapEx
$-467,000
Dividends Paid
—
Buybacks
$-5,000
EPS Diluted TTM
$-3.17
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-351,935,000
Inventory
—
Receivables
$171,000
ST Investments
$320,275,000
EBIT TTM
$-167,616,000
Pretax Income TTM
$-150,470,000
Interest Exp TTM
—
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,000,000
EBITDA
$-166,714,000
Free Cash Flow
$-75,277,000
Enterprise Value
$1,063,156,160
Total Cash
$395,028,992
Total Debt
$9,391,000
Shares Out
59,279,630
Trailing EPS
$-3.17
Book Value
$8.13
ROE
-33.3%
ROA
-22.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -125,099,000 -111,483,000 512,431,000 27,778,000 484,653,000 -87,473,000
Dec 2024 0 -83,055,000 -78,307,000 314,933,000 9,506,000 305,427,000 -64,828,000
Dec 2023 0 -36,179,000 -34,786,000 155,423,000 181,057,000 -25,634,000 -27,181,000
Dec 2022 — — — 31,603,000 41,665,000 -10,062,000 —

TTM Snapshot

Revenues TTM
$27,807,000
NetIncome TTM
$-137,160,000
OpCashFlow TTM
—
Assets (Latest)
$458,982,000
Forward EPS
$-4.15

Max Pain — expiry 2026-12-18

max pain strike: $25.00 · spot: $23.40 · call oi: 2,672 · put oi: 515
Expected Move to 2026-12-18: ±$4.25 (18.16%) — implied range $19.15 – $27.65 · ATM straddle on $22.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DMRA Damora Therapeutics, Inc. $1.40B $22.56 —
NBTX Nanobiotix S.A. $1.39B $27.45 —
NUVB Nuvation Bio Inc. $1.37B $3.90 —
PCRX Pacira BioSciences, Inc. $1.46B $36.48 —
QURE uniQure N.V. $1.46B $20.78 —

News headlines (Yahoo Finance, 1h cache)

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
2026-11-04 12:00 · Yahoo
Rapport Therapeutics to Participate in Upcoming Investor Conferences
2026-11-03 12:00 · Yahoo
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, a
2026-11-02 12:00 · Yahoo
Rapport Therapeutics Prices Stock, Convertible Notes Offerings; Private Placement; Shares Fall
2026-10-28 14:59 · Yahoo
Rapport Therapeutics stock tumbles on $350M capital raise
2026-10-28 13:45 · Yahoo
Rapport Therapeutics Sinks 22% on Discounted $350 Million Stock and Convertible Note Raise
2026-10-28 13:03 · Yahoo
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
2026-10-28 10:00 · Yahoo
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
2026-10-27 20:32 · Yahoo
Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania Data
2026-10-23 08:11 · Yahoo
Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania Data
2026-10-23 00:16 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.